TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20472745

Group type: EXPERIMENTAL
Intervention: Akreos Adapt IOL
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: AcrySof SA60AT IOL
Number of subjects: 122
Study: 18760123

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 16005384

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg of D‐amphetamine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12404670

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (paroxetine and citalopram)
Number of subjects: 0
Study: 10624541

Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo rTMS
Number of subjects: 13
Study: 7729392

Group type: EXPERIMENTAL
Intervention: Negative slope keyboard support system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full motion forearm supports
Number of subjects: 0

Group type: COMPARATOR
Intervention: No arm support (control)
Number of subjects: 0
Study: 2158260

Group type: EXPERIMENTAL
Intervention: ICI 204,219 (40 mg oral dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 335584

Group type: EXPERIMENTAL
Intervention: PUFA preparation
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (oleic acid)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups (PUFA and placebo)
Number of subjects: 89
Study: 31767368

Group type: EXPERIMENTAL
Intervention: Low ST cluster
Number of subjects: 574

Group type: COMPARATOR
Intervention: High ST cluster
Number of subjects: 574

Group type: COMPARATOR
Intervention: Gamers cluster
Number of subjects: 574

Group type: COMPARATOR
Intervention: High cellphone cluster
Number of subjects: 574
Study: 30193936

Group type: EXPERIMENTAL
Intervention: Reslizumab (3 mg/kg IV) every 4 weeks for 52 weeks
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 28333534

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Individual therapy (IT)
Number of subjects: 276
Study: 26223506

Group type: EXPERIMENTAL
Intervention: Topical agent A (20% aluminum chloride hexahydrate)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Topical agent B (1% aluminum acetate)
Number of subjects: 19
Study: 23223947

Group type: EXPERIMENTAL
Intervention: 10 mg ropivacaine and 2 μg sufentanil in 30 mL 0.9% saline (Group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10 mg ropivacaine in 30 mL 0.9% saline (Group C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2 μg sufentanil in 30 mL 0.9% saline (Group D)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 30 mL of 0.9% saline (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group B (ropivacaine with sufentanil)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group B, C, or D
Number of subjects: 80
Study: 20850880

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 766
Study: 18180761

Group type: EXPERIMENTAL
Intervention: Brief intensive cognitive-behavioral therapy (CBT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal controls (no treatment)
Number of subjects: 10
Study: 17101026

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 105
Study: 14751554

Group type: EXPERIMENTAL
Intervention: Training at 10 degrees in the upper visual field
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Training at 10 degrees in the lower visual field
Number of subjects: 18

Group type: COMPARATOR
Intervention: No-training control group
Number of subjects: 18
Study: 11693075

Group type: EXPERIMENTAL
Intervention: Pharmaceutical Care (PhC)
Number of subjects: 735

Group type: COMPARATOR
Intervention: Traditional pharmacy practice (Control)
Number of subjects: 735
Study: 9383924

Group type: EXPERIMENTAL
Intervention: Various interventions in pediatric psychology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive assessment of health and psychological outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Innovative treatment applications and strategies to integrate research and practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case series to document promising methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of costs versus benefits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 0
Study: 7523480

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody based kits
Number of subjects: 240

Group type: COMPARATOR
Intervention: RIA
Number of subjects: 240

Group type: COMPARATOR
Intervention: Monoclonal antibodies specific for the holohormone (anti-alpha beta)
Number of subjects: 240
Study: 2464094

Group type: EXPERIMENTAL
Intervention: Dilevalol (400 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Isoproterenol (160 and 480 micrograms)
Number of subjects: 16
Study: 30039790

Group type: EXPERIMENTAL
Intervention: Single quadrant injection technique (Group S)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Two quadrants injection technique (Group C)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Postoperative VAS after surgery
Number of subjects: 57
Study: 27485318

Group type: EXPERIMENTAL
Intervention: OV/OB youth with asthma
Number of subjects: 142

Group type: COMPARATOR
Intervention: OV/OB youth only
Number of subjects: 142
Study: 26365445

Group type: EXPERIMENTAL
Intervention: Acupuncture (twice weekly for 8 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no anti-hypertensive treatment for 12 weeks)
Number of subjects: 30
Study: 24262440

Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab
Number of subjects: 1579

Group type: EXPERIMENTAL
Intervention: Predefined cut points for predictive model
Number of subjects: 1579
Study: 21175845

Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) bolus abciximab
Number of subjects: 355

Group type: COMPARATOR
Intervention: Intravenous (IV) bolus abciximab
Number of subjects: 355
Study: 18496310

Group type: EXPERIMENTAL
Intervention: Continuous nasogastric feeding
Number of subjects: 70

Group type: COMPARATOR
Intervention: Bolus nasogastric feeding
Number of subjects: 70

Group type: COMPARATOR
Intervention: Bolus orogastric feeding
Number of subjects: 70
Study: 16712437

Group type: EXPERIMENTAL
Intervention: Simple No in smoking refusal
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Alternatives in shoplifting refusal
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Declarative Statements in smoking refusal
Number of subjects: 454
Study: 15742998

Group type: EXPERIMENTAL
Intervention: 20 small polyethylene radiopaque cylinders (5 mm x 2 mm in diameter) with a standard solid meal (790 Kcal)
Number of subjects: 48
Study: 11293461

Group type: EXPERIMENTAL
Intervention: Computational model based on neuropsychological theory of category learning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal decision rules (complex piecewise quadratic functions)
Number of subjects: 0
Study: 9146775

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg effervescent
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg effervescent
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg capsules
Number of subjects: 12
Study: 8190296

Group type: EXPERIMENTAL
Intervention: Entacapone (acute and chronic administration)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Entacapone (after withdrawal)
Number of subjects: 15
Study: 3064647

Group type: EXPERIMENTAL
Intervention: Oxazepam 30 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31951276

Group type: EXPERIMENTAL
Intervention: Circulating proportions of B cells
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Circulating proportions of B cells among premenopausal women
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Circulating proportions of monocytes among premenopausal women
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Higher monocyte proportions
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Higher B cell proportions
Number of subjects: 2774
Study: 30835626

Group type: EXPERIMENTAL
Intervention: Pre-academic abilities
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Self-regulation
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Peer relations
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Parental education
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Emotion knowledge assessment
Number of subjects: 1034
Study: 28335745

Group type: EXPERIMENTAL
Intervention: Capsaicin (0.6%, 12 cm2, application duration: 15 min)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine (25/25 mg, 10 cm2, application duration: 60 min)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Co-application of Capsaicin and Lidocaine/Prilocaine (Cap/LA and LA/Cap)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Co-application of Capsaicin and Lidocaine/Prilocaine (LA/Cap)
Number of subjects: 28
Study: 25647536

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Playing soccer
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study: 23314743

Group type: EXPERIMENTAL
Intervention: LCI699 (0.5 mg b.i.d. for 14 days, then 1 mg b.i.d. for 15 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Eplerenone (50 mg b.i.d., up-titrated to 100 mg b.i.d. in 12/14 patients)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Eplerenone (50-100 mg b.i.d.)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: LCI699 (0.5-1 mg b.i.d.)
Number of subjects: 14
Study: 22108151

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin (10/20 or 10/40 mg)
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Atorvastatin (10, 20, or 40 mg)
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin (10/20-40 mg)
Number of subjects: 1143

Group type: COMPARATOR
Intervention: All doses (ezetimibe/simvastatin and atorvastatin)
Number of subjects: 1143
Study: 19604319

Group type: EXPERIMENTAL
Intervention: Hypnotic intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control condition (simple relaxation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (Hypnosis and Control)
Number of subjects: 40
Study: 17197848

Group type: EXPERIMENTAL
Intervention: 0.5% propofol
Number of subjects: 64

Group type: COMPARATOR
Intervention: 1.0% propofol
Number of subjects: 64
Study: 15166915

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba special extract EGb 761 (2 x 120 mg/day for 7 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11784875

Group type: COMPARATOR
Intervention: cisplatin and paclitaxel
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: cisplatin and gemcitabine
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: cisplatin and docetaxel
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: carboplatin and paclitaxel
Number of subjects: 1207
Study: 9713935

Group type: EXPERIMENTAL
Intervention: diphtheria‐tetanus‐acellular pertussis (dTap) vaccine
Number of subjects: 235

Group type: COMPARATOR
Intervention: diphtheria‐tetanus (dT) vaccine
Number of subjects: 235
Study: 8064352

Group type: EXPERIMENTAL
Intervention: Constant velocity trajectory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unpredictable velocity trajectory
Number of subjects: 0
Study: 2840652

Group type: EXPERIMENTAL
Intervention: Metoclopramide (doses adjusted to each individual case)
Number of subjects: 10
Study: 30033035

Group type: EXPERIMENTAL
Intervention: PB-IORT
Number of subjects: 34

Group type: COMPARATOR
Intervention: WBI-DIBH
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: IORT
Number of subjects: 34
Study: 28495811

Group type: EXPERIMENTAL
Intervention: Online education programme
Number of subjects: 180

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 180
Study: 25556965

Group type: EXPERIMENTAL
Intervention: Viscotrabeculotomy (VT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional trabeculotomy (T)
Number of subjects: 41
Study: 22975439

Group type: EXPERIMENTAL
Intervention: Primary Clinical Event Committee (CEC) adjudication
Number of subjects: 2292

Group type: EXPERIMENTAL
Intervention: Harmonization recommendations applied to the overall RAC population
Number of subjects: 2292
Study: 20677606

Group type: EXPERIMENTAL
Intervention: 5.0% lignocaine 75 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: 0.5% bupivacaine 12.5 mg
Number of subjects: 52
Study: 17571086

Group type: EXPERIMENTAL
Intervention: Brimonidine/timolol fixed combination (BTFC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Unfixed combination of brimonidine and timolol
Number of subjects: 28
Study: 16648043

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (20 mg/kg bodyweight)
Number of subjects: 322

Group type: COMPARATOR
Intervention: White light (conventional microsurgery)
Number of subjects: 322
Study: 12954243

Group type: EXPERIMENTAL
Intervention: Prophylactic flucloxacillin
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 11030854

Group type: EXPERIMENTAL
Intervention: Safer Choices intervention
Number of subjects: 345
Study: 8780294

Group type: EXPERIMENTAL
Intervention: Sufentanil 3 microgram/kg induction in Group M (ventilated via mask)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sufentanil 3 microgram/kg induction in Group E (ventilated via endotracheal tube)
Number of subjects: 40
Study: 1623029

Group type: EXPERIMENTAL
Intervention: Procedure plus sensation (experimental)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Procedure (control)
Number of subjects: 22
Study: 6382004

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg twice a day
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg twice a day
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at bedtime
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Cimetidine in smokers
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo in smokers
Number of subjects: 370
Study: 30001704

Group type: EXPERIMENTAL
Intervention: Mindfulness for Bipolar 2.0
Number of subjects: 300

Group type: COMPARATOR
Intervention: Psychoeducation for Bipolar
Number of subjects: 300
Study: 26804670

Group type: EXPERIMENTAL
Intervention: 5-alpha reductase inhibitors (5-ARIs)
Number of subjects: 6537

Group type: COMPARATOR
Intervention: Alpha-blockers
Number of subjects: 6537
Study: 24607046

Group type: EXPERIMENTAL
Intervention: MP29-02, one spray per nostril twice daily (total daily doses of azelastine hydrochloride and FP were 548 mcg and 200 mcg, respectively)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP), 2 sprays per nostril once daily (total daily dose 200 mcg)
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: MP29-02
Number of subjects: 612

Group type: COMPARATOR
Intervention: MP29-02 and FP
Number of subjects: 612
Study: 22396230

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) using cloth covered cooling gel packs for 72 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no therapeutic hypothermia)
Number of subjects: 0
Study: 20178792

Group type: EXPERIMENTAL
Intervention: Fibrin glue injections (n = 36)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Observation (n = 41)
Number of subjects: 77
Study: 18566461

Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Number of subjects: 484

Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 484
Study: 15777971

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 105
Study: 12804929

Group type: EXPERIMENTAL
Intervention: Single chamber pacemakers
Number of subjects: 307

Group type: COMPARATOR
Intervention: Dual chamber pacemakers
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Chronic atrial fibrillation
Number of subjects: 307

Group type: COMPARATOR
Intervention: Sinus rhythm
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: History of ischaemic heart disease
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Years of pacing
Number of subjects: 307
Study: 10745303

Group type: EXPERIMENTAL
Intervention: Growth hormone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8701480

Group type: EXPERIMENTAL
Intervention: Inhalation therapy with magnesium sulfate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhalation therapy with salbutamol sulfate
Number of subjects: 20
Study: 1512329

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy
Number of subjects: 1330
Study: 6859073

Group type: EXPERIMENTAL
Intervention: Nitrates (large doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term nitrate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31836583

Group type: EXPERIMENTAL
Intervention: Nebulised surfactant
Number of subjects: 32

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 32
Study: 30200925

Group type: EXPERIMENTAL
Intervention: Family Partners for Health intervention (for African American children)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family Partners for Health intervention (for white children)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family Partners for Health intervention (for African American parents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family Partners for Health intervention (for white parents)
Number of subjects: 0
Study: 26910903

Group type: EXPERIMENTAL
Intervention: MRI-guided laser interstitial thermal therapy (laser ablation)
Number of subjects: 20
Study: 24744317

Group type: EXPERIMENTAL
Intervention: FA plus 30 mg of iron (IFA)
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: FA, iron, plus 13 additional micronutrients (MM)
Number of subjects: 834

Group type: COMPARATOR
Intervention: Folic acid (FA) (control)
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: FA plus 30 mg of iron (IFA) and FA, iron, plus 13 additional micronutrients (MM)
Number of subjects: 834
Study: 22185768

Group type: EXPERIMENTAL
Intervention: Passive Movement Therapy (PMT) three times a week for four weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no PMT)
Number of subjects: 101
Study: 20671078

Group type: EXPERIMENTAL
Intervention: Pressure Ulcer Classification education tool (PUCLAS)
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1217
Study: 17492901

Group type: EXPERIMENTAL
Intervention: Various treatment modalities for chronic pelvic pain
Number of subjects: 0
Study: 15901015

Group type: EXPERIMENTAL
Intervention: Phosphoric acid etching with saliva contamination
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NRC etching with saliva contamination
Number of subjects: 18

Group type: COMPARATOR
Intervention: Phosphoric acid etching without saliva contamination
Number of subjects: 18

Group type: COMPARATOR
Intervention: NRC etching without saliva contamination
Number of subjects: 18
Study: 12501064

Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 119
Study: 11317375

Group type: EXPERIMENTAL
Intervention: ChemFil superior without conditioner
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: ChemFil superior with conditioner
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Fuji II LC with conditioner
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: ChemFil superior with and without conditioner
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ketac-Fil
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Conventional glass-ionomer cements (C-GIC)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Photac-Fil quick
Number of subjects: 96
Study: 8973996

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1601764

Group type: EXPERIMENTAL
Intervention: Cefpirome 1g bd
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Cefpirome 2g bd
Number of subjects: 276
Study: 4061020

Group type: EXPERIMENTAL
Intervention: Suxamethonium during halothane inhalation in group I (children under 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Suxamethonium during halothane inhalation in group II (children over 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Suxamethonium during halothane inhalation in group III (children over 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pancuronium and thiopentone during intravenous induction in group III (children over 10)
Number of subjects: 40
Study: 30843873

Group type: EXPERIMENTAL
Intervention: Transcutaneous (t.c.) administration of trivalent influenza vaccine (TIV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) administration of trivalent influenza vaccine (TIV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) administration of trivalent influenza vaccine (TIV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Early innate gene signature
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nine genes and serum level of CXCL10
Number of subjects: 60
Study: 30538429

Group type: EXPERIMENTAL
Intervention: Single doses of roflumilast (0.25, 0.375, and 0.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple doses of roflumilast (0.375 mg once daily for 11 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Safety evaluation (monitoring, physical examination, vital sign tests, clinical laboratory tests)
Number of subjects: 12
Study: 27813422

Group type: EXPERIMENTAL
Intervention: BI 695501 (40 mg subcutaneous dose)
Number of subjects: 327

Group type: COMPARATOR
Intervention: US-approved Humira (40 mg subcutaneous dose)
Number of subjects: 327

Group type: COMPARATOR
Intervention: EU-approved Humira (40 mg subcutaneous dose)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: BI 695501, US-approved Humira, EU-approved Humira
Number of subjects: 327